Navigation Links
Bayer HealthCare to Sponsor World Federation of Hemophilia Global Training Program and Donate Kogenate® FS, Antihemophilic Factor (Recombinant), Commercially Valued At More Than $7 Million
Date:4/28/2011

MONTVILLE, N.J., and MONTREAL, April 28, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia (WFH) are announcing a three-year extension of Bayer's sponsorship agreement with WFH.  The agreement calls for Bayer to serve as sole sponsor of WFH's International Hemophilia Training Centre (IHTC) program, in addition to providing support for other WFH activities, such as its Web site and Congress.  Established in 1969, the IHTC program gives health care professionals from developing countries training in the diagnosis and management of hemophilia and related bleeding disorders.  Additionally, Bayer has made a major donation to WFH of Kogenate® FS, antihemophilic factor (recombinant), a recombinant factor VIII treatment for hemophilia A, which will be used for humanitarian aid in countries where persons with hemophilia A have limited access to care.  The donated Kogenate FS is commercially valued at more than $7 million.

The IHTC program provides clinical, laboratory and paramedical training in 28 centers worldwide, located in the Americas, Africa and the Middle East, Asia, Western Pacific and Europe.  Most recently, a new center was designated in Russia in 2010, and plans are underway to establish a center in Egypt.

"The International Hemophilia Training Centre program is critical to furthering the treatment of hemophilia and related disorders around the world," said Claudia Black, WFH CEO.  "We appreciate our long-standing partnership with Bayer, and commend the company on its commitment to the hemophilia community to help us achieve our vision of Treatment for All."

The centers provide training in all aspects of hemophilia management, with 35 fellowships awarded each year.  Fellowship candidates are chosen based on their level of commitment and potential to improve hemophilia treatment in their country, after the completion of their training period.  Fellowsh
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... LONDON , July 14, 2014  VirtualScopics, ... (AIM: IXI) jointly announced today the formation of a ... Edward Ashton , Ph.D., chief scientific officer, VirtualScopics, ... members. "The formation of this joint Scientific ... commercial and operational alliance we signed with IXICO plc ...
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
Breaking Medicine Technology:VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2
... Calif., April 29, 2011 First Quarter ... by 321 institutions, up from 239 in Q4 2010 ... revenue Operational focus enables lower planned expense growth in ... by Astellas NGX-1998 Phase 2 clinical trial continues in ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... cancers and infectious diseases, announced today that the company will ... Securities Research Conference San Francisco, CA, May 9-11, 2011 ... Dr. J. Joseph Kim, Ph.D., President & CEO May ...
Cached Medicine Technology:NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:7/14/2014)... 14, 2014 Many people are unhappy ... plastic surgery to reduce a “double chin.” A ... the need to go under the knife. Jawflex is ... jaw muscles, therefore tightening the skin in that area ... Jawflex is used for facial exercise, double chin elimination ...
(Date:7/14/2014)... Many diet plans often recommend eating plenty ... School of Public Health at the University of Alabama ... effect on weight loss. Now experts are suggesting that the ... of portion control to trigger measurable weight loss. ... controlling how much is consumed, simply by using a specially-designed ...
(Date:7/14/2014)... Seattle, WA (PRWEB) July 14, 2014 ... start up company Passionate Playground announces its first product ... adult pleasure product storage system. , Inventor ... for passionate consumers to have a storage solution for ... in the multibillion dollar adult retail industry. , Semer ...
(Date:7/14/2014)... 14, 2014 EurekaMag.com has newly published ... is a contagious liver disease that ranges in ... to a serious, lifelong illness that attacks the liver. ... have chronic Hepatitis C virus infection of which approximately ... research category covers all studies on Hepatitis C ...
(Date:7/14/2014)... "Medical devices, tests, and treatments are critical ... is a star when it comes to innovations in ... working on amazing products and ideas that are our ... to Dale Kaye CEO of the Innovation Tri-Valley ... brilliant minds and businesses that are leading society into ...
Breaking Medicine News(10 mins):Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4
... of its,mission to help consumers feel better and lead ... WNI ), introduces two new,products that help maintain health ... Nutrition is key to staying healthy, but sometimes the ... compounds into our bodies. Schiff(R),3-Day Cleanse is a simple ...
... To World-Class ... Knowledge-Based Economy, ... Business at,Carnegie Mellon University and its Donald H. Jones ... Pittsburgh: Building Bridges to a City,s New Future." The,symposium, ...
... Comprehensive Eating,Disorders Program at Lucile Packard Children,s Hospital ... 18 to 21. This allows the program to,now ... "I am delighted that the Eating Disorders ... group," said Naomi Brown, PhD, an eating,disorders treatment ...
... trials reported using independent safety monitoring committees that can ... reactions, according to a major review published in the ... University of Nottingham carried out a detailed analysis of ... to see what safety measures were in place to ...
... http://www.pharmacyfraudsettlement.com with filed documents, fraud, allegations, ... ... As front line professionals dispensing medications to,Medicaid beneficiaries pharmacists are particularly ... and report Medicaid fraud, which is noted in the site., ...
... Peake: VA Reaches Out to Vets, Families in ... veterans and,their families during major emergencies, especially natural ... to deploy mobile pharmacies,that will provide vital medicine ... will also open up the facilities to help ...
Cached Medicine News:Health News:Schiff(R) Introduces New Supplement Products for Intestinal Health and Beauty Maintenance 2Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 2Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 3Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 4Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 5Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 6Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 2Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 3Health News:Only 2 percent of child drug trials have independent safety checks 2Health News:Only 2 percent of child drug trials have independent safety checks 3Health News:CVS, America's Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges 2Health News:CVS, America's Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges 3Health News:VA Putting Mobile Pharmacies on the Road 2
... Protection Device features the ability to use ... lesion and a pre-loaded nitinol filter with ... Offering a fully rapid exchange system, the ... the indicated applications:, Carotid Indication - ,The ...
Clot-based Assay for Anti-FXa and/or Anti-Iia Therapies...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: